DNTH
Dianthus Therapeutics, Inc.
Set alert
82.38 USD -0.32 -0.39%
80.63 Day range 83.73
33.20 52-week range 115.96
- YTD
- +99.90%
- 1 year
- +144.16%
- Open
- 81.29
- Prev close
- 82.70
- Mkt cap
- 4.61B
- Vol
- 496.89K
- Avg vol
- 822.37K
- EPS
- -4.24
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 80.63
- High
- 83.73
- Forward P/E
- -17.87
- Beta
- 0.18
- Short ratio
- 9.16
- Inst. own
- 128.66%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 93.30
- 200-d avg
- 84.85
- 1y target
- 139.06
Key statistics
- Market cap
- 4.50B
- Enterprise value
- 3.74B
- Trailing P/E
- 0.00
- Forward P/E
- -17.87
- PEG ratio
- 0.00
- Price / sales
- 2365.23
- Price / book
- 3.85
- EPS (TTM)
- -4.24
- Beta
- 0.18
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.90M
- Revenue growth
- 294.30%
- Free cash flow
- -92.21M
- Total cash
- 886.81M
- Total debt
- 1.29M
- Return on equity
- -26.06%
- Shares outstanding
- 54.67M
- Short % of float
- 18.43%
- 50-day average
- 93.30
- 200-day average
- 84.85
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 139.06 +68.8% upside
Now 82.38
- Target (low)
- 113.00
- Target (mean)
- 139.06
- Target (high)
- 200.00
Ratings (0m) 18 18 buy · 0 hold · 0 sell
- Strong buy1
- Buy17
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.94865.
Financials — quick view
DNTH Revenue — quarterly 761.00K
DNTH Net income — quarterly -50.22M
DNTH EPS — quarterly -0.90
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.94454 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | -0.84628 | -0.90 | -0.05 | -6.35% |
| May 5, 2026 | Mar 31, 2026 | -1.17 | -0.85 | +0.32 | +27.35% |
| Mar 9, 2026 | Dec 31, 2025 | -0.98 | -1.43 | -0.45 | -45.92% |
| Nov 5, 2025 | Sep 30, 2025 | -0.86 | -0.97 | -0.11 | -12.79% |
| Aug 7, 2025 | Jun 30, 2025 | -0.86 | -0.88 | -0.02 | -2.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 27, 2026 | Roth Capital | init | — | Buy |
| Oct 15, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 11, 2026 | JP Morgan | init | — | Overweight |
| Sep 4, 2026 | Citigroup | init | — | Buy |
| Aug 6, 2026 | Truist Securities | main | Buy | Buy |
| Aug 6, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- dianthustx.com
News
- This PPL Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
- Roth Capital Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $113
- HC Wainwright & Co. Reiterates Buy on Dianthus Therapeutics, Maintains $158 Price Target
- Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharma
- Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
- Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting
- This Shopify Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
- JP Morgan Initiates Coverage On Dianthus Therapeutics with Overweight Rating, Announces Price Target of $135
- Dianthus Therapeutics, Inc. (DNTH) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Your note
Sign in to keep a note on DNTH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARR EDWARD | Officer | Conversion of Exercise of derivative security | Mar 11, 2026 | 0 |
| GARCIA MARINO | Chief Executive Officer | Conversion of Exercise of derivative security | Aug 6, 2026 | 65,292 |
| MCGEORGE ANNE | Director | Conversion of Exercise of derivative security | Aug 9, 2026 | 0 |
| RANDHAWA SIMRAT | Officer | Conversion of Exercise of derivative security | Aug 31, 2026 | 4,000 |
| READ SIMON J. | Director | Conversion of Exercise of derivative security | Aug 18, 2026 | 0 |
| SAVITZ RYAN | Chief Financial Officer | Conversion of Exercise of derivative security | Jul 8, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.96% | 8,199,893 | 675.51M | Jun 29, 2026 |
| Blackrock Inc. | 7.53% | 4,123,822 | 339.72M | Jun 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 7.10% | 3,888,456 | 320.33M | Jun 29, 2026 |
| Wellington Management Group, LLP | 5.89% | 3,229,882 | 266.08M | Jun 29, 2026 |
| Fairmount Funds Management LLC | 4.63% | 2,537,191 | 209.01M | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 4.59% | 2,514,946 | 207.18M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.01% | 1,649,920 | 135.92M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.91% | 1,592,149 | 131.16M | Aug 30, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 2.74% | 1,503,955 | 123.90M | Jul 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.52% | 1,380,523 | 113.73M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.23% | 1,224,305 | 100.86M | Sep 29, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 2.11% | 1,155,511 | 95.19M | Jun 29, 2026 |